Iqvia Hldgs Inc - IQV STOCK NEWS

IQVIA Holdings Inc. (NYSE: IQV) will announce its fourth-quarter and full-year 2022 financial results on February 10, 2023, before market opens. The management team will host a conference call at 9:00 a.m. Eastern Time the same day. Investors can access the earnings release and related financial information on the IQVIA Investor Relations website. To participate in the call, prior registration is required. A replay of the webcast will be available two hours post-event. IQVIA is a leading global provider of analytics, technology solutions, and clinical research services, employing approximately 86,000 staff across over 100 countries.

The IQVIA Institute for Human Data Science reports that global spending on medicines is projected to reach $1.9 trillion by 2027, with a growth rate of 3-6% driven by new drug launches. The cumulative pharmaceutical market is expected to increase by $500 billion due to COVID-19, primarily from vaccines. Oncology spending will rise to $370 billion by 2027. Specialty medicines will account for 43% of global spending, while biotech spending will reach 35% by 2027. Increased drug access primarily in Latin America, Asia, and Africa contrasts with slow growth in North America and Europe.

Lasso, an IQVIA business, has expanded its Measurement Suite by integrating IQVIA's AIM XR, granting over 4,000 medical publishers access to enhanced insights on campaign reach and effectiveness.

This integration aims to simplify audience and campaign measurement for healthcare publishers, improving efficiency and breaking down barriers to return on investment.

With real-world impact studies and sales analysis capabilities, the initiative enhances healthcare communications and supports better decision-making and patient care.

IQVIA (NYSE:IQV) announced a long-term collaboration with Clalit, Israel's largest health organization, to launch its first Prime Site in Israel. This partnership aims to enhance clinical trial delivery and real-world research through combined expertise in data analytics and genomics. Clalit, which operates 14 hospitals and over 1600 clinics, will utilize its Prime Site designation to provide patients with access to advanced therapies. The collaboration is expected to transform healthcare and pharmaceutical research, positioning Israel as a hub for innovation.

IQVIA Holdings Inc. reported Q3 2022 revenue of $3,562 million, up 5.0% year-over-year, achieving a GAAP net income of $283 million, an increase of 8.4%. Adjusted EBITDA rose 11.8% to $814 million. R&D Solutions booked over $2.5 billion in quarterly bookings, with a record $2.0 billion excluding pass-throughs, yielding a book-to-bill ratio of 1.39x. The contracted backlog reached $25.8 billion, up 5.4%. For FY 2022, revenue guidance is updated to $14.325-14.425 billion, reflecting growth despite macroeconomic challenges.

IQVIA Holdings Inc. (NYSE:IQV) announced that CFO Ron Bruehlman will present at the Credit Suisse Annual Healthcare Conference on November 8, 2022, at 12:10 p.m. ET in Rancho Palos Verdes. A live webcast of the event will be available on the IQVIA Investor Relations website, with a replay accessible later the same day. IQVIA is a global provider of analytics and technology solutions in the life sciences sector, employing around 83,000 people across over 100 countries, focusing on enhancing healthcare through innovative treatments.

Q² Solutions, a subsidiary of IQVIA, has launched the first self-collection safety lab panel for U.S. clinical trial participants. This service, developed with Tasso Inc, allows patients to collect blood samples at home, enhancing convenience and reducing the need for clinical visits. The initial panel monitors liver function through various enzyme and protein tests. Q² Solutions aims to expand this offering with over a dozen additional safety tests, emphasizing patient-centered design and logistics optimization.

IQVIA Holdings Inc. (NYSE:IQV) is set to announce its third-quarter 2022 financial results before the market opens on October 26, 2022. The management team will host a conference call at 9:00 a.m. ET on the same day, with details available on the IQVIA Investor Relations website. A replay of the webcast will be accessible about two hours after the event. IQVIA is a leader in analytics, technology solutions, and clinical research for life sciences, employing approximately 83,000 individuals in over 100 countries.

IQVIA (NYSE:IQV) announced its Decentralized Clinical Trial (DCT) program is the first to receive GDPR compliance validation from TRUSTArc, enhancing its commitment to data protection in Europe. This validation ensures that personal data in decentralized trials is processed in accordance with GDPR, addressing privacy concerns for participants. The achievement reinforces IQVIA's dedication to delivering decentralized studies while improving diversity and sustainability in clinical development, as emphasized by key executives.